| Literature DB >> 32581713 |
Xingxing Chen1,2,3, Ning Xin4, Yongcheng Pan3,5, Louyin Zhu3, Peng Yin2, Qiong Liu3,5, Weili Yang2, Xingshun Xu6, Shihua Li2, Xiao-Jiang Li2.
Abstract
Huntingtin-associated protein 1 (Hap1) was initially identified as a brain-enriched protein that binds to the Huntington's disease protein, huntingtin. Unlike huntingtin that is ubiquitously expressed in the brain, Hap1 is enriched in the brain with the highest expression level in the hypothalamus. The selective enrichment of Hap1 in the hypothalamus suggests that Hap1 may play a specific role in hypothalamic function that can regulate metabolism and stress response. Here we report that Hap1 is colocalized and interacts with the glucocorticoid receptor (GR) in mouse hypothalamic neurons. Genetic depletion of Hap1 reduced the expression level of GR in the hypothalamus. Dexamethasone, a GR agonist, treatment or fasting of mice induced stress, resulting in increased expression of Hap1 in the hypothalamus. However, when Hap1 was absent, these treatments promoted GR reduction in the hypothalamus. In cultured cells, loss of Hap1 shortened the half-life of GR. These findings suggest that Hap1 stabilizes GR in the cytoplasm and that Hap1 dysfunction or deficiency may alter animal's stress response.Entities:
Keywords: Huntington’s disease; glucocorticoid receptor; hypothalamus; protein stability; stress
Year: 2020 PMID: 32581713 PMCID: PMC7289054 DOI: 10.3389/fncel.2020.00125
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Figure 1Interaction of Huntingtin-associated protein 1 (Hap1) with glucocorticoid receptor (GR). Double-immunofluorescent labeling of GR and Hap1 in the mouse paraventricular nucleus (PVN). (A) The sagittal section of a mouse in DAPI staining and red box indicating PVN in hypothalamus. (B,C) The high-power images from the red box, GR-immunoreactive cells (B), and HAP1-immunoreactive cells (C). (D) Merged image of (B,C). Scale bar: 50 μm. (E) An enlarged image of the white square region of (D) showing clear double immunofluorescence for GR (green) and HAP1 (red). Scale bar: 20 μm. (F) Immunoprecipitation of endogenous GR from the hypothalamic tissues of WT mice showing the coprecipitation of GR and Hap1.
Figure 2The expression level of GR in hypothalamus was reduced in Hap1 KO mice. (A) Representative fluorescence images of GR (green), Hap1 (red), and merged fluorescence with nuclear (blue) labeling in PVN of wild-type or Hap1-null mouse at P1. Scale bar: 50 μm. (B) Western blotting result showing that the GR protein level of hypothalamic tissues decreased in the knockout (KO) mice at P1 as compared to wild-type mouse. Vinculin served as an internal control. (C) The ratios of GR to vinculin on the Western blots were obtained from three independent experiments. Mean ± SEM; **P < 0.01; one-way ANOVA with Tukey post hoc test.
Figure 3Depletion of Hap1 expression affects Dex-mediated GR expression in early development. (A) Western blot result showing that the GR protein level of hypothalamic tissues decreased in the Hap1-null mice at P1 and P3 as compared to wild-type mouse. Note that the decrease was much more dramatic 6 h after i.p. Dex administration. Vinculin served as an internal control. (B) The ratios of GR to vinculin were presented. (C) Relative levels of Hap1 (ratio to vinculin) on the Western blots were obtained from three independent experiments. Mean ± SEM; *P < 0.05; **P < 0.01; one-way ANOVA with Tukey post hoc test.
Figure 4Hap1 deficiency affects the expression of hypothalamic GR in adult mice after Dex administration and fasting. (A) A schematic of the Tamoxifen (TM)-inducible Cre/loxP system to delete Hap1 in adult mouse. Exon 1 of the mouse Hap1 gene was flanked by two loxP sites and the neomycin-resistant (neo) gene for generating floxed Hap1 mice. The floxed Hap1 mice were crossed with transgenic mice expressing Cre-ER, resulting in disruption of the Hap1 gene. (B,C) Representative Western blotting (B) and quantification (C) of GR and HAP1 protein levels after Dex administration, showing that the GR protein level was decreased in the hypothalamus of adult Hap1 KO mice. The inducible Hap1-KO mice were treated with TM at 2 months of age. At 4 months of age, they were i.p. injected with Dex (1 mg/kg) and analyzed 6 h later. Data are presented as mean ± SEM; *P < 0.05; **P < 0.01. (D,E) Representative Western blotting (D) and quantification (E) of GR and Hap1 levels in the hypothalamus of control and adult Hap1 KO mice after a 24-h fast, showing that the GR expression was further decreased in the hypothalamus of adult Hap1 KO mice compared with WT control mice. Results were obtained from three independent experiments. Mean ± SEM; *P < 0.05; **P < 0.01.
Figure 5Loss of Hap1 shortened the half-life of GR in N2a cells. (A) Schematics of the designed Hap1-gRNA. (B) Schematics of AAV-Hap1-gRNA and AAV-CMV-Cas9 vectors. (C) Western blotting assay shows Hap1 reduction in N2a cells that were cotransfected with Hap1 gRNA and Cas9 plasmids. (D) Quantitative analysis of Western blotting results in (C). Data are presented as mean ± SEM; **P < 0.01. (E) Western blot analysis of half-life of GR in transfected N2a cells that were treated with CHX for different times (0, 6, 12, 24, 36 h) to inhibit protein synthesis. (F) The relative protein levels of GR were assessed by densitometric analysis of their bands on Western blots, and the value at 0 h was considered 100%. Results were obtained from three independent experiments. Mean ± SEM; **P < 0.01.